In terms of progression from healthy liver to metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis, we do not know when exactly the downregulation of adiponectin occurs and whether this downregulation merely exacerbates disease progression or whether it serves as a disease initiator. The gene discussed is ADIPOQ; the disease is liver disorder.